SynthesisBMC palliative care2025
"Nebulized lidocaine for intractable cough in hospice care: a comprehensive review of efficacy, safety, and future perspectives".
Synthesis in BMC palliative care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lidocaine Delivery Systems for Preventing Postoperative Sore Throat: From Direct Spray to Soft Mist.Local and regional anesthesia · 2026Review
- Unraveling the neuro-immune axis in cough hypersensitivity: from pathogenesis to synergistic management.Frontiers in medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectiveIntractable cough, affecting 10-50% of terminally ill patients, significantly impairs quality of life. Conventional therapies often fail due to dose-limiting side effects or inadequate efficacy, necessitating alternative treatments. This review evaluates the efficacy, safety, and clinical applicability of nebulized lidocaine for managing intractable cough in hospice care.
methodsA systematic literature search (1973-2023) across PubMed, MEDLINE, Embase, and Cochrane Library identified studies on nebulized lidocaine in hospice or palliative populations. Inclusion criteria the Cochrane Risk of Bias Tool and Newcastle-Ottawa Scale. Data on cough reduction, side effects, and dosing were synthesized thematically.
resultsAmong 265 screened studies, 58 met inclusion criteria. Nebulized lidocaine (1-4%) demonstrated rapid cough suppression (within 15 min) in 70% of cancer patients, with effects lasting 2-4 h. Mild side effects, including oropharyngeal numbness (15%) and bitter taste (10%), were transient. However, 25% of asthmatic patients experienced bronchoconstriction (forced expiratory volume in 1 s FEV1FEV1 decline ≥ 15%), resolving with bronchodilators. Lidocaine reduced opioid reliance and improved comfort in 80% of cases. Variability in efficacy was noted, with limited benefits in severe chronic obstructive pulmonary disease (COPD) with acute respiratory failure.
conclusionNebulized lidocaine offers a safe, non-invasive option for intractable cough in hospice care, minimizing systemic side effects. Its rapid action and compatibility with opioid-sparing regimens enhance palliative outcomes. However, cautious use is warranted in asthma and (COPD) due to bronchoconstriction risks. Future research should prioritize standardized dosing, long-term safety, and Randomized controlled trials(RCTs in diverse hospice populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.